Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube Dec 20, 2025
Company Medical Device

Alcon Laboratories’ Innovative Intraocular Lens Approved by China’s NMPA

Fineline Cube Apr 20, 2023

The National Medical Products Administration (NMPA) has granted import approval to US firm Alcon Laboratories,...

Company Drug

Biosyngen Receives US FDA IND Approval for T-Cell Redirection Therapy for EBV-Positive Lymphoma

Fineline Cube Apr 19, 2023

Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...

Company Deals

EOC Pharma Group Partners with China National Accord Medicines for Distribution Rights

Fineline Cube Apr 19, 2023

China-based EOC Pharma Group has announced a strategic partnership with compatriot firm China National Accord...

Company Deals

Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform

Fineline Cube Apr 19, 2023

Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...

Company Deals

Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System

Fineline Cube Apr 19, 2023

Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens...

Company Drug

Shandong Jincheng Pharmaceutical Initiates Phase II Study for LT-01 Antibacterial Drug

Fineline Cube Apr 19, 2023

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), China’s largest cephalosporin manufacturer, has announced receiving...

Company Deals

RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System

Fineline Cube Apr 19, 2023

RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...

Company Deals R&D

Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research

Fineline Cube Apr 19, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...

Company Deals

Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China

Fineline Cube Apr 19, 2023

China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...

Company Drug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...

Medical Device Policy / Regulatory

National Center Reports Increase in Medical Device Adverse Event Reports for 2022

Fineline Cube Apr 19, 2023

The National Center for Adverse Event Monitoring has released its national annual report regarding the...

Policy / Regulatory

China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog

Fineline Cube Apr 19, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Deals

China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab

Fineline Cube Apr 19, 2023

China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...

Company Drug

XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor

Fineline Cube Apr 19, 2023

XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment...

Company Drug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...

Company Drug

BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination

Fineline Cube Apr 18, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...

Company Drug

HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein

Fineline Cube Apr 18, 2023

Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a...

Company Deals

Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China

Fineline Cube Apr 18, 2023

The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership...

Company Deals

Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing

Fineline Cube Apr 18, 2023

Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions...

Company Drug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

Fineline Cube Apr 18, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 469 470 471 … 600

Recent updates

  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
  • Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.